Cargando…
Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis
OBJECTIVE: This study aimed to compare the efficacy and safety of different platinum adjuvant chemotherapy regimens for early-stage resected non-small-cell lung cancer (NSCLC). DESIGN: Systematic review with network meta-analysis of randomised trials. DATA SOURCES: PubMed, EMBASE, The Cochrane Libra...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196189/ https://www.ncbi.nlm.nih.gov/pubmed/35697451 http://dx.doi.org/10.1136/bmjopen-2021-057098 |
_version_ | 1784727129113493504 |
---|---|
author | Pang, Lan-Lan Gan, Jia-Di Huang, Yi-Hua Liao, Jun Lv, Yi Ali, Wael Abdullah-Sultan Zhang, Li Fang, Wen-Feng |
author_facet | Pang, Lan-Lan Gan, Jia-Di Huang, Yi-Hua Liao, Jun Lv, Yi Ali, Wael Abdullah-Sultan Zhang, Li Fang, Wen-Feng |
author_sort | Pang, Lan-Lan |
collection | PubMed |
description | OBJECTIVE: This study aimed to compare the efficacy and safety of different platinum adjuvant chemotherapy regimens for early-stage resected non-small-cell lung cancer (NSCLC). DESIGN: Systematic review with network meta-analysis of randomised trials. DATA SOURCES: PubMed, EMBASE, The Cochrane Library, Web of Science and Scopus Google Scholar were searched through 12 March 2021. ELIGIBILITY CRITERIA: Eligible randomised controlled trials (RCTs) comparing the postoperative platinum chemotherapy regimen with the observation-controlled group or comparing two platinum chemotherapy regimens head-to-head were included. DATA EXTRACTION AND SYNTHESIS: The primary outcome was the efficacy of adjuvant chemotherapy regimens including relapse-free survival (RFS), overall survival (OS), 2-year, 3-year, 5-year RFS rate and OS rate. The secondary outcome was the rate of grade 3–4 toxicity assessments. Cochrane Handbook (V.5) was used for the risk of bias assessment. Analyses were performed using R software V.4.3.1. RESULTS: 20 RCTs with a sample size of 5483 were enrolled in meta-analysis. The chemotherapy group had a significant RFS and OS advantage compared with the observation group (HR 0.67; 95% CI 0.56 to 0.81, p<0.0001; HR 0.80; 95% CI, 0.73 to 0.88, p<0.0001, respectively). Compared with the observation arm, only the ‘cisplatin_vinorelbine’ regimen had a significant RFS and OS advantage (HR 0.63; 95% CI 0.43 to 0.87; HR 0.74; 95% CI 0.63 to 0.87, respectively) while the remaining chemotherapy regimens had no significant difference of efficacy compared with the observation group. In terms of the safety of adjuvant chemotherapy, the incidence of haematological toxicities and nausea/vomiting was not significantly higher in the ‘cisplatin_vinorelbine’ arm than in other chemotherapy group. CONCLUSION: This study summarised the adjuvant cytotoxicity chemotherapy regimens for patients with early-stage resected NSCLC. Our analysis may provide some guiding significance for the clinicians when determining the optimal chemotherapy regimen. |
format | Online Article Text |
id | pubmed-9196189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91961892022-07-08 Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis Pang, Lan-Lan Gan, Jia-Di Huang, Yi-Hua Liao, Jun Lv, Yi Ali, Wael Abdullah-Sultan Zhang, Li Fang, Wen-Feng BMJ Open Oncology OBJECTIVE: This study aimed to compare the efficacy and safety of different platinum adjuvant chemotherapy regimens for early-stage resected non-small-cell lung cancer (NSCLC). DESIGN: Systematic review with network meta-analysis of randomised trials. DATA SOURCES: PubMed, EMBASE, The Cochrane Library, Web of Science and Scopus Google Scholar were searched through 12 March 2021. ELIGIBILITY CRITERIA: Eligible randomised controlled trials (RCTs) comparing the postoperative platinum chemotherapy regimen with the observation-controlled group or comparing two platinum chemotherapy regimens head-to-head were included. DATA EXTRACTION AND SYNTHESIS: The primary outcome was the efficacy of adjuvant chemotherapy regimens including relapse-free survival (RFS), overall survival (OS), 2-year, 3-year, 5-year RFS rate and OS rate. The secondary outcome was the rate of grade 3–4 toxicity assessments. Cochrane Handbook (V.5) was used for the risk of bias assessment. Analyses were performed using R software V.4.3.1. RESULTS: 20 RCTs with a sample size of 5483 were enrolled in meta-analysis. The chemotherapy group had a significant RFS and OS advantage compared with the observation group (HR 0.67; 95% CI 0.56 to 0.81, p<0.0001; HR 0.80; 95% CI, 0.73 to 0.88, p<0.0001, respectively). Compared with the observation arm, only the ‘cisplatin_vinorelbine’ regimen had a significant RFS and OS advantage (HR 0.63; 95% CI 0.43 to 0.87; HR 0.74; 95% CI 0.63 to 0.87, respectively) while the remaining chemotherapy regimens had no significant difference of efficacy compared with the observation group. In terms of the safety of adjuvant chemotherapy, the incidence of haematological toxicities and nausea/vomiting was not significantly higher in the ‘cisplatin_vinorelbine’ arm than in other chemotherapy group. CONCLUSION: This study summarised the adjuvant cytotoxicity chemotherapy regimens for patients with early-stage resected NSCLC. Our analysis may provide some guiding significance for the clinicians when determining the optimal chemotherapy regimen. BMJ Publishing Group 2022-06-12 /pmc/articles/PMC9196189/ /pubmed/35697451 http://dx.doi.org/10.1136/bmjopen-2021-057098 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Oncology Pang, Lan-Lan Gan, Jia-Di Huang, Yi-Hua Liao, Jun Lv, Yi Ali, Wael Abdullah-Sultan Zhang, Li Fang, Wen-Feng Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis |
title | Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis |
title_full | Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis |
title_fullStr | Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis |
title_full_unstemmed | Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis |
title_short | Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis |
title_sort | investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a bayesian network meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196189/ https://www.ncbi.nlm.nih.gov/pubmed/35697451 http://dx.doi.org/10.1136/bmjopen-2021-057098 |
work_keys_str_mv | AT panglanlan investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis AT ganjiadi investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis AT huangyihua investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis AT liaojun investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis AT lvyi investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis AT aliwaelabdullahsultan investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis AT zhangli investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis AT fangwenfeng investigationoftheoptimalplatinumbasedregimeninthepostoperativeadjuvantchemotherapysettingforearlystageresectednonsmalllungcancerabayesiannetworkmetaanalysis |